Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 11, 2026, 10:22 PM ET
PepGen Announces Pricing of $125 Million Public Offering
Nasdaq: $PEPGBiotech · Myotonic dystrophyU.S. partial clinical hold · Dilution
PEPG Stock Hub: PepGen News, DM1 Data and Clinical Development
PepGen reported 46.5% mean splicing correction in six patients treated at 10 mg/kg in FREEDOM2-DM1, with descriptive improvements in muscle-function measures. The next data window is January 2027 for FREEDOM-OLE, followed by the 12.5 mg/kg cohort in the first half of 2027. At September 30, 2026, cash, cash equivalents and marketable securities totaled $104.805 million, with company guidance into 2028. The $125 million offering priced on November 11, 25,000,000 shares at $5.00 with closing expected on or about November 13, and the continuing U.S. partial clinical hold remain central financial and regulatory risks.
Research Library · Biotech
PepGen: DM1 data, clinical risk and the funding path
Mechanism, trials, safety, financial statements, capital structure, governance and risks.
Next catalyst · Company guidance
January 2027 · FREEDOM-OLE update
Interim clinical data at 5 mg/kg and safety data at 10 mg/kg. These are different dose groups and data types. November 10 outlook
Before the data: on November 11, PepGen priced 25,000,000 shares of common stock at $5.00 each for $125 million of gross proceeds, before underwriting discounts, commissions and offering expenses; closing is expected on or about November 13, 2026, subject to customary closing conditions. Pricing release. The FDA hold has no announced resolution date.
PEPG stock: dated clinical and financial snapshot
Regular close
$5.26
November 11, 2026 · Nasdaq; $4.61 on November 10
Equity value
$364.314M
Calculated: $5.26 × 69,261,282 shares; share count November 4, before the priced offering
Cash and securities
$104.805M
September 30, 2026 · before the November offering
Q3 net loss
$19.391M
Quarter ended September 30, 2026
Operating cash use
$47.407M
Nine months ended September 30, 2026
Common shares
69.261M
November 4, 2026 cover-page count
Splicing correction
46.5%
10 mg/kg · n=6 treated · Week 13
Priced offering
$125M
Gross · 25,000,000 shares at $5.00 · priced November 11, 2026 · closing expected on or about November 13
Quarterly filing · Clinical data · Preliminary offering · Offering pricing. Equity value is a calculation using the latest cover-page share count; it excludes the 25,000,000 shares priced on November 11 and any shares from the underwriters’ option, which had not been issued at that count date.
PepGen DM1 data: the signal and its limits
The FDA partial hold remains in place in the United States. The hold followed nonclinical findings in mice. Clinical data from the ongoing multinational study do not by themselves remove it. The 10 mg/kg results involved six treated participants and two concurrent placebo participants; the reported splicing comparator pooled four placebo participants across the first two cohorts.
▲ The constructive case
Splicing correction increased with dose and was accompanied by descriptive changes in hand-opening time, grip strength and mobility. The 12.5 mg/kg cohort was fully enrolled, and longer follow-up in FREEDOM-OLE can address durability. Management’s existing-resource guidance extended into 2028 before proceeds from the offering priced on November 11, which is expected to raise $125 million of gross proceeds, before underwriting discounts, commissions and expenses, if it closes as expected.
▼ The cautious case
Small samples, pooled placebo and exploratory functional measures cannot establish confirmatory efficacy. Patient-reported outcomes were inconclusive or mixed. Four mild renal adverse events occurred in the 10 mg/kg cohort; the separate extension recorded a hypersensitivity-related discontinuation. The November 11 pricing adds 25,000,000 new shares at $5.00, below the $5.26 close that day; they equal about 36% of the 69,261,282 shares outstanding on November 4, or about 41% if the underwriters buy all 3,750,000 optional shares (Merlintrader calculation). Resolution of the U.S. hold remains a material issue.
Latest PEPG news
Nov 11, 2026
PepGen Announces Pricing of $125 Million Public Offering
PepGen announced the pricing of a $125 million public offering. Only the headline is available for this item.
Nov 10, 2026
PepGen announces proposed $125.0 million public offering of common stock
PepGen launched a public offering of $125.0 million of shares of its common stock, with pre-funded warrants offered in lieu of common stock to certain investors. It intends to grant underwriters a 30-day option to purchase up to an additional $18.75 million of shares. Net proceeds are intended to fund ongoing clinical development of its product candidate, working capital and general corporate purposes. Leerink Partners, Stifel and Guggenheim Securities are joint bookrunning managers.
Nov 10, 2026
PepGen reports third quarter 2026 financial results and recent corporate highlights
PepGen reported financial results for the quarter ended September 30, 2026, with Cash, Cash Equivalents and Marketable Securities of $104.8 million, sufficient to fund operations into 2028. Research and Development Expenses were $14.5 million and General and Administrative Expenses were $5.9 million for the three months ended September 30, 2026. Net Loss was $19.4 million, or $(0.28) basic and diluted net loss per share. The release also covered positive 10 mg/kg FREEDOM2-DM1 results with a mean splicing correction of 46.5%.
Nov 10, 2026
PepGen announces positive Phase 2 FREEDOM2-DM1 10 mg/kg results with highest reported splicing correction
PepGen Inc. reported topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial of PGN-EDODM1 in myotonic dystrophy type 1. Mean splicing correction in muscle reached 46.5% at Week 13, with five of six participants above 20% and four above 50%. Video Hand Opening Time improved by 3.9 seconds (52.7%) at Week 16, while placebo improved 0.2 seconds. PGN-EDODM1 was generally well tolerated, with no serious or severe adverse events or dose-limiting toxicities reported.
PEPG stock catalysts: FREEDOM-OLE and FREEDOM2-DM1
- November 11, 2026 — Public offering priced: 25,000,000 shares of common stock at $5.00, $125 million of expected gross proceeds; 30-day underwriter option for up to 3,750,000 additional shares. Completed · pricing
- On or about November 13, 2026 — Expected closing of the offering, subject to customary closing conditions. Company expectation
- January 2027 — FREEDOM-OLE: interim clinical data at 5 mg/kg and safety data at 10 mg/kg. Company guidance · November 10
- First half of 2027 — Results from the fully enrolled 12.5 mg/kg FREEDOM2-DM1 cohort. Company guidance
- Second half of 2027 — Planned FDA end-of-Phase 2 meeting, pending removal of the partial clinical hold. Conditional company guidance
- Undated — U.S. partial-hold response and resolution; longer-term expansion cohort. Conditional milestones
Company development outlook · Preliminary financing terms · Offering pricing. Registry primary-completion estimates are different from company data-release guidance.
PepGen pipeline: PGN-EDODM1 and the EDO platform
MECHANISM
PGN-EDODM1
A peptide-conjugated oligonucleotide designed to bind expanded CUG repeats in pathogenic DMPK RNA, release MBNL1 and improve RNA splicing while preserving normal DMPK function. It remains investigational.
PHASE 2
FREEDOM2-DM1
NCT06667453: randomized, double-blind, placebo-controlled multiple ascending doses. The 10 mg/kg cohort included eight participants randomized 3:1, with four doses every four weeks. The 12.5 mg/kg cohort was fully enrolled as of November 10.
FOLLOW-UP
FREEDOM-OLE
NCT07220603: an open-label extension for eligible participants. Nineteen participants were enrolled as of November 10, with more than 35 doses at 10 mg/kg and 100 doses at 5 mg/kg administered. Open-label observations have a different evidentiary basis from blinded comparisons.
Pipeline concentration. The current development focus is DM1. PepGen discontinued the former PGN-EDO51 Duchenne muscular dystrophy program; the current clinical pipeline is concentrated on DM1.
Current pipeline · Program history and risks · Mechanism and design.
FREEDOM2-DM1 10 mg/kg: endpoints, safety and interpretation
WEEK 13 · SPLICING
46.5% mean correction
Six treated participants; five exceeded 20% correction and four exceeded 50%. The pooled placebo mean was 6.8% in four participants across Cohorts 1 and 2. The result used a 22-gene panel.
WEEK 16 · FUNCTION
Descriptive improvements
Video hand-opening time improved 3.9 seconds (52.7%) from baseline. Grip strength improved 16.2%, corresponding to 6.3 percentage points of predicted normal. TUG improved 8.5%; the 10-meter walk/run improved 6.8%. Patient-reported outcomes were inconclusive or mixed.
WEEK 16 · SAFETY
Short-term cohort results
No serious or severe events, dose-limiting toxicities or discontinuations in the 10 mg/kg cohort. Four renal adverse events were mild, with transient albuminuria. Longer exposure and larger populations remain necessary to characterize risk.
November 10 clinical release. These are early-cohort observations, not evidence of a completed pivotal trial or an FDA approval.
Merlintrader Health Score · $PEPG
3.10out of 5
Reassessed November 12, 2026, after the November 11 offering pricing; scores unchanged: the dilution score already reflected the proposed offering, and the balance-sheet score does not count offering proceeds before closing. Weighted calculation: 4.0 × 30% + 3.0 × 30% + 2.0 × 20% + 3.0 × 10% + 3.0 × 10% = 3.10 out of 5. The score describes financial and operational robustness over twelve to eighteen months. It is not an indication to buy or sell.
September 2026 Form 10-Q · Clinical data · Preliminary prospectus · Offering pricing
PEPG red flags
- Partial U.S. clinical hold remains unresolved; additional nonclinical work is needed.
- The 10 mg/kg active cohort had six participants; pooled placebo and descriptive functional changes limit inference.
- Patient-reported outcome measures were inconclusive or mixed.
- Renal events and a separate extension hypersensitivity discontinuation require ongoing safety follow-up.
- The $125 million offering priced on November 11 adds 25,000,000 shares at $5.00, up to 28,750,000 with the underwriters’ option, roughly 36% to 41% of the November 4 share count (Merlintrader calculation); closing is expected on or about November 13, 2026.
- The company remains loss-making and depends on successful clinical development and future funding.
- Options, RSUs and additional capital issuance can dilute common shareholders.
- Discontinuation of PGN-EDO51 leaves the clinical pipeline concentrated on DM1.
PEPG Stock FAQ: PepGen Questions Answered
When is the next PEPG stock catalyst?
As of November 11, 2026, PepGen expected interim FREEDOM-OLE clinical data at 5 mg/kg and safety data at 10 mg/kg in January 2027. Results from the fully enrolled 12.5 mg/kg FREEDOM2-DM1 cohort were expected in the first half of 2027. These are company guidance windows rather than fixed release dates. Program outlook.
Is PepGen PGN-EDODM1 approved by the FDA?
As of November 11, 2026, PGN-EDODM1 was investigational and not FDA-approved. FREEDOM2-DM1 remained under a partial clinical hold in the United States after nonclinical findings in mice. The planned end-of-Phase 2 FDA meeting in the second half of 2027 depended on removal of that hold. Orphan and Fast Track designations do not constitute marketing approval. Regulatory update · Study and designation details.
How much cash does PepGen have, and how long will it last?
At September 30, 2026, PepGen had $104.805 million of cash, cash equivalents and marketable securities. Management expected those existing resources to fund planned operations into 2028. Nine-month operating cash use was $47.407 million. The offering priced on November 11 was not included in the September balance; its $125 million is a gross figure before underwriting discounts, commissions and expenses, and becomes cash only at closing, expected on or about November 13, 2026. Quarterly financial statements · Cash-runway guidance.
Is PEPG stock at risk of dilution from the offering?
Yes: on November 11, 2026, PepGen priced 25,000,000 new shares of common stock at $5.00 each, for expected gross proceeds of $125 million. The underwriters have a 30-day option to buy up to 3,750,000 additional shares, and closing is expected on or about November 13, 2026, subject to customary closing conditions. Before the offering, 69,261,282 common shares were outstanding on November 4. At September 30, 7,995,891 stock options and 1,067,795 restricted stock units were also outstanding. Offering pricing · Share count and awards.
When does PepGen report earnings?
As of November 11, 2026, PepGen had not announced its next earnings date. Its latest results, published November 10, covered the quarter ended September 30, 2026. Quarterly net loss was $19.391 million, with research and development expense of $14.476 million and general and administrative expense of $5.907 million. Latest quarterly results.
What does PepGen do?
As of November 11, 2026, PepGen was a clinical-stage biotechnology company developing peptide-conjugated oligonucleotides for serious genetic diseases. Its lead candidate, PGN-EDODM1, targets toxic expanded-repeat RNA in myotonic dystrophy type 1. It aims to release RNA-splicing proteins while preserving normal DMPK function. The candidate remains in clinical development. Company and mechanism overview.
What did PepGen report in the FREEDOM2-DM1 trial?
On November 10, 2026, PepGen reported 46.5% mean splicing correction at Week 13 in six participants treated at 10 mg/kg, compared with 6.8% in four pooled placebo participants. At Week 16, video hand-opening time improved 3.9 seconds, or 52.7%, from baseline. The small cohort and descriptive functional findings do not establish confirmatory efficacy. Clinical results.
What safety findings did PepGen report at 10 mg/kg?
On November 10, 2026, PepGen reported no serious or severe adverse events, dose-limiting toxicities or treatment discontinuations in the 10 mg/kg FREEDOM2 cohort through Week 16. Four mild renal adverse events and transient albuminuria were reported. Separately, the open-label extension had one discontinuation due to a hypersensitivity reaction. The extension and the randomized cohort had different safety populations and observation periods. Cohort safety · Extension update.
Primary sources
- Pricing of $125 million public offering · November 11, 2026
- Form 10-Q · September 30, 2026 · filed November 10
- Third-quarter results and program outlook · November 10, 2026
- FREEDOM2-DM1 10 mg/kg data · November 10, 2026
- Preliminary offering prospectus · November 10, 2026
- 2025 Form 10-K · filed March 4, 2026
- ClinicalTrials.gov · FREEDOM2-DM1
- ClinicalTrials.gov · FREEDOM-OLE
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $PEPG or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
